Proteomic Analysis of Sarcoma: Molecular Differences between Benign and Malignant Tumors of Bone and Soft Tissue
The proteomic profiles of bone and soft tissue sarcomas remain largely unexplored. The “proteome” represents all protein isoforms expressed within a target tissue, including those with post-translational modifications. We are using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and liquid chromatography/tandem mass spectrometry (LC-MS/MS) to evaluate proteomic differences between selected sarcomas and their presumed benign counterparts and/or normal tissues. The specific aim of this proposal is to identify sarcoma-specific differences in protein expression that define the malignant phenotype. These findings may elucidate important mechanisms in sarcoma development and lead to novel diagnostic and therapeutic strategies.